Bora Pharmaceuticals is a premier international contract development and manufacturing organization (CDMO) specializing in complex oral solid dose, liquids, semi-solids and nasal sprays for pharmaceutical Rx and OTC products. We operate from early phase clinical right through to commercial manufacturing with full packaging capabilities.
Bikash Chatterjee of Pharmatech Associates discusses the reshoring trend, technologies and advances that could help deliver more manufacturing back to the U.S.
Veklury (remdesivir) with sales of $829 million offsets loss of exclusivity of Truvada and Atripla in the U.S. with sales down 72% and 42%, respectively.
Biovac will perform manufacturing and distribution activities within Pfizer’s and BioNTech’s global COVID-19 vaccine supply chain and manufacturing network.
CDMOs have been some of the biggest winners from COVID contracts and will see benefits for several more years to come. A Q&A with GlobalData’s Peter Shapiro.
Lonza’s Robert Beland discusses best practices for manufacturers to shorten development timelines, as well as some of the capabilities at the CDMO's Tampa site.
How today’s life sciences manufacturers can effectively monitor processes, integrate with sub-contractors and align with regulatory reporting requirements.
Dr. Murphy of ICON, provider of clinical services to Pfizer/BioNTech’s COVID vaccine program, discusses what it takes to conduct a vaccine trial of this scale.
As a partner to the U.S. Government, GRAM's newest facility was designed to increase large-scale fill and finish capacity with room to expand as demand grows.
Fran L. DeGrazio of West discusses why and how vaccine development is different than drug development and the impacts of COVID-19 on vaccine development.
Dr. Ural of Ernst & Young LLP discusses market dynamics, enduring therapeutic areas, near term M&A, and how industry can use this time for transformation
Serge Bodart of IDDI provides insight on the pharma and biopharma trends impacting CROs, outsourcing in today’s market, and advances in clinical research.
JoyL Silva of Pfizer CentreOne discusses global market and regulatory changes driving drug development strategies and the evolution of CDMO services and ops.
Andrew Kolbert of Avomeen discusses FDA oversight of E&L testing, complications that arise, and the expertise needed to keep up with changing quality standards
Senior Product Manager, Ben Wylie, sat down with Contract Pharma to discuss new company developments and technology, along with emerging industry trends
The chief executive talks industry trends, challenges and what’s in store for PCI Pharma Services as it continues its rapid growth and global expansion strategy
Michael Felo, Director, Downstream Process Integration, Next Generation Processing, MilliporeSigma shares his insight with Contract Pharma at Interphex 2019
The use of electronic tongue technology helps firms reduce development times and costs by overcoming challenges associated with traditional testing panels.
Detlev Haack & Martin Koeberle, Hermes Pharma03.06.19
IDDI, BMS Consortium aims to establish that the GPC statistical method can complement the design, analysis and interpretation of clinical trial results
A roundtable discussion about the serialization challenge and why some contract service providers and brand owners are skeptical of each other's readiness
Contract Pharma asked a roundtable of business leaders from Symbiosis, Grifols, Althea, LSNE and Baxter to discuss key trends in the parenteral dosage development and manufacturing market
Niall Dinwoodie of Charles River discusses several key industry issues on biosimilars and addresses some of the development and regulatory hurdles that remain
Pharma teamed up with ICON, Tufts CSDD and other industry players to author new book detailing holistic reforms for trial design, clinical ops, and portfolios